Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 654

1.

A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.

Kokabi N, Galt JR, Xing M, Camacho JC, Barron BJ, Schuster DM, Kim HS.

J Vasc Interv Radiol. 2014 Feb;25(2):277-87. doi: 10.1016/j.jvir.2013.11.007.

PMID:
24461133
2.

Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.

Padia SA, Alessio A, Kwan SW, Lewis DH, Vaidya S, Minoshima S.

J Vasc Interv Radiol. 2013 Aug;24(8):1147-53. doi: 10.1016/j.jvir.2013.04.018. Epub 2013 Jun 20.

PMID:
23792126
3.

Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.

Garin E, Rolland Y, Edeline J, Icard N, Lenoir L, Laffont S, Mesbah H, Breton M, Sulpice L, Boudjema K, Rohou T, Raoul JL, Clement B, Boucher E.

J Nucl Med. 2015 Mar;56(3):339-46. doi: 10.2967/jnumed.114.145177. Epub 2015 Feb 12.

4.

Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.

Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, Porée P, Clément B, Raoul JL, Boucher E.

J Nucl Med. 2012 Feb;53(2):255-63. doi: 10.2967/jnumed.111.094235.

5.

Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.

Haste P, Tann M, Persohn S, LaRoche T, Aaron V, Mauxion T, Chauhan N, Dreher MR, Johnson MS.

J Vasc Interv Radiol. 2017 May;28(5):722-730.e1. doi: 10.1016/j.jvir.2016.12.1221. Epub 2017 Feb 24.

PMID:
28238581
6.

Outpatient single-session yttrium-90 glass microsphere radioembolization.

Gates VL, Marshall KG, Salzig K, Williams M, Lewandowski RJ, Salem R.

J Vasc Interv Radiol. 2014 Feb;25(2):266-70. doi: 10.1016/j.jvir.2013.11.005. Epub 2013 Dec 12.

PMID:
24332243
7.

Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.

Burgmans MC, Kao YH, Irani FG, Dames EL, Teo TK, Goh AS, Chow PK, Tay KH, Lo RH.

J Vasc Interv Radiol. 2012 Oct;23(10):1294-301. doi: 10.1016/j.jvir.2012.07.009. Epub 2012 Aug 24.

PMID:
22922039
8.

Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.

Ilhan H, Goritschan A, Paprottka P, Jakobs TF, Fendler WP, Todica A, Bartenstein P, Hacker M, Haug AR.

J Nucl Med. 2015 Nov;56(11):1654-60. doi: 10.2967/jnumed.115.162685. Epub 2015 Aug 27.

9.

Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.

Eaton BR, Kim HS, Schreibmann E, Schuster DM, Galt JR, Barron B, Kim S, Liu Y, Landry J, Fox T.

J Vasc Interv Radiol. 2014 Feb;25(2):288-95. doi: 10.1016/j.jvir.2013.08.021. Epub 2013 Oct 23.

PMID:
24269792
10.

SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer.

Hamami ME, Poeppel TD, Müller S, Heusner T, Bockisch A, Hilgard P, Antoch G.

J Nucl Med. 2009 May;50(5):688-92. doi: 10.2967/jnumed.108.058347. Epub 2009 Apr 16.

11.

Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.

Ozkan ZG, Poyanli A, Ucar A, Kuyumcu S, Akyuz F, Keskin S, Saglam S, Yilmaz E, Karaca C, Turkmen C.

Cancer Biother Radiopharm. 2015 Apr;30(3):132-8. doi: 10.1089/cbr.2014.1748. Epub 2015 Mar 11.

PMID:
25760644
12.

Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.

Lea WB, Tapp KN, Tann M, Hutchins GD, Fletcher JW, Johnson MS.

J Vasc Interv Radiol. 2014 Oct;25(10):1595-603. doi: 10.1016/j.jvir.2014.06.028. Epub 2014 Aug 23.

PMID:
25156647
13.

Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.

Kokabi N, Camacho JC, Xing M, El-Rayes BF, Spivey JR, Knechtle SJ, Kim HS.

Cancer. 2015 Jul 1;121(13):2164-74. doi: 10.1002/cncr.29275. Epub 2015 Apr 6.

14.

Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.

Demirelli S, Erkilic M, Oner AO, Budak ES, Gunduz S, Ozgur O, Bozcuk H, Sindel HT, Boz A.

Nucl Med Commun. 2015 Apr;36(4):340-9. doi: 10.1097/MNM.0000000000000257.

PMID:
25563137
15.

Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.

Gnesin S, Canetti L, Adib S, Cherbuin N, Silva Monteiro M, Bize P, Denys A, Prior JO, Baechler S, Boubaker A.

J Nucl Med. 2016 Nov;57(11):1672-1678. Epub 2016 Jun 15.

16.

Characteristics of primary and secondary hepatic malignancies associated with hepatopulmonary shunting.

Gaba RC, Zivin SP, Dikopf MS, Parvinian A, Casadaban LC, Lu Y, Bui JT.

Radiology. 2014 May;271(2):602-12. doi: 10.1148/radiol.14131969. Epub 2014 Feb 12.

PMID:
24533871
17.

Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis.

Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M, Courtney A.

J Vasc Interv Radiol. 2004 Apr;15(4):335-45.

PMID:
15064336
18.

Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.

Iñarrairaegui M, Thurston KG, Bilbao JI, D'Avola D, Rodriguez M, Arbizu J, Martinez-Cuesta A, Sangro B.

J Vasc Interv Radiol. 2010 Aug;21(8):1205-12. doi: 10.1016/j.jvir.2010.04.012. Epub 2010 Jul 3.

PMID:
20598574
19.

Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.

Biederman DM, Titano JJ, Tabori NE, Pierobon ES, Alshebeeb K, Schwartz M, Facciuto ME, Gunasekaran G, Florman S, Fischman AM, Patel RS, Nowakowski FS, Kim E.

J Vasc Interv Radiol. 2016 Jun;27(6):812-821.e2. doi: 10.1016/j.jvir.2016.01.147. Epub 2016 Apr 7.

PMID:
27062356
20.

Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.

Golfieri R, Bilbao JI, Carpanese L, Cianni R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Cappelli A, Rodriguez M, Ettorre GM, Saltarelli A, Geatti O, Ahmadzadehfar H, Haug AR, Izzo F, Giampalma E, Sangro B, Pizzi G, Notarianni E, Vit A, Wilhelm K, Jakobs TF, Lastoria S; European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators.

J Hepatol. 2013 Oct;59(4):753-61. doi: 10.1016/j.jhep.2013.05.025. Epub 2013 May 23.

PMID:
23707371

Supplemental Content

Support Center